









市場行情
/
股票
/
nasdaq-adct
/

ADC Therapeutics SA

ADCT

3.451USD

-0.249-6.72%

交易中（美東）報價延遲15分鐘

388.71M總市值

虧損本益比TTM



ADC Therapeutics SA

3.451

-0.249-6.72%

概覽公司財務分析

概覽

公司

財務

分析

關於 ADC Therapeutics SA 公司

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

ADC Therapeutics SA簡介



公司代碼ADCT

公司名稱ADC Therapeutics SA

上市日期May 15, 2020

CEOMallik (Ameet)

員工數量263

證券類型Ordinary Share

年結日May 15

公司地址Biopole

城市EPALINGES

上市交易所NASDAQ OMX NASDAQ Basic NYSE

國家Switzerland

郵編1066

電話41216530200

網址https://adctherapeutics.com/

公司代碼ADCT

上市日期May 15, 2020

CEOMallik (Ameet)

ADC Therapeutics SA公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Ron R. Squarer

Non-Executive Chairman of the Board

1.58M

+1.60%

Mr. Ameet Mallik

Chief Executive Officer, Director

1.31M

-15.07%

Mr. Mohamed Zaki, M.D., Ph.D.

Chief Medical Officer

601.26K

-6.39%

Mr. Jose (Pepe) Carmona

Chief Financial Officer

351.57K

-13.15%

Mr. Peter J. Graham

Chief Legal and Compliance Officer and Secretary

311.53K

-13.71%

Dr. Peter Hug, Ph.D.

Non-Executive Vice Chairman of the Board, Lead Independent Director

180.50K

+26.54%

Ms. Viviane Monges

Non-Executive Independent Director

134.98K

+38.35%

Dr. Victor Sandor, M.D.

Non-Executive Independent Director

99.40K

+38.06%

Mr. Robert W. (Bob) Azelby

Non-Executive Independent Director

55.26K

+98.35%

Mr. Timothy P. (Tim) Coughlin, CPA

Director

40.00K

名稱

名稱/職務

職務

持股

持股變動

Mr. Ron R. Squarer

Non-Executive Chairman of the Board

1.58M

+1.60%

Mr. Ameet Mallik

Chief Executive Officer, Director

1.31M

-15.07%

Mr. Mohamed Zaki, M.D., Ph.D.

Chief Medical Officer

601.26K

-6.39%

Mr. Jose (Pepe) Carmona

Chief Financial Officer

351.57K

-13.15%

Mr. Peter J. Graham

Chief Legal and Compliance Officer and Secretary

311.53K

-13.71%

Dr. Peter Hug, Ph.D.

Non-Executive Vice Chairman of the Board, Lead Independent Director

180.50K

+26.54%

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月18日週二

持股股東

股東類型

持股股東

佔比

Redmile Group, LLC

12.65%

HPWH TH AG

7.00%

Point72 Asset Management, L.P.

6.57%

Prosight Capital

6.03%

OrbiMed Advisors, LLC

4.77%

其他

62.99%

持股股東

佔比

Redmile Group, LLC

12.65%

HPWH TH AG

7.00%

Point72 Asset Management, L.P.

6.57%

Prosight Capital

6.03%

OrbiMed Advisors, LLC

4.77%

其他

62.99%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

21.83%

Hedge Fund

16.53%

Corporation

8.80%

Investment Advisor

8.55%

Research Firm

6.43%

Individual Investor

4.96%

Private Equity

4.77%

Bank and Trust

0.39%

Venture Capital

0.07%

其他

27.66%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

191

72.94M

63.83%

-1.48K

2025Q3

203

72.94M

76.75%

+266.41K

2025Q2

196

72.67M

64.60%

+13.50M

2025Q1

198

59.17M

80.56%

-20.65M

2024Q4

201

60.84M

78.41%

+1.63M

2024Q3

204

59.22M

80.70%

+2.20M

2024Q2

196

56.12M

64.88%

+18.35M

2024Q1

159

35.17M

75.47%

-27.30M

2023Q4

158

34.44M

76.49%

-6.23M

2023Q3

162

40.67M

76.05%

-5.62M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Redmile Group, LLC

15.67M

13.93%

Jun 30, 2025

HPWH TH AG

8.67M

7.71%

-1.12M

-11.42%

May 15, 2025

Point72 Asset Management, L.P.

7.76M

6.9%

+7.76M

Jun 30, 2025

Prosight Capital

10.47M

9.3%

+924.77K

+9.69%

Jun 30, 2025

OrbiMed Advisors, LLC

5.91M

5.25%

-61.10K

-1.02%

Jun 30, 2025

Oaktree Capital Management, L.P.

4.02M

3.57%

+4.02M

Apr 25, 2024

BlackRock Institutional Trust Company, N.A.

4.06M

3.6%

-442.92K

-9.85%

Jun 30, 2025

Morgan Stanley & Co. LLC

2.99M

2.66%

+33.76K

+1.14%

Jun 30, 2025

Nantahala Capital Management, LLC

2.27M

2.01%

+2.27M

Jun 30, 2025

Auven Therapeutics General LP

2.23M

1.98%

-4.10M

-64.75%

Apr 23, 2024

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Micro-Cap ETF

0.06%

SPDR S&P International Small Cap ETF

0.04%

iShares Biotechnology ETF

0.03%

iShares Russell 2000 Growth ETF

0.02%

ProShares UltraPro Russell2000

0.01%

ProShares Hedge Replication ETF

0.01%

Proshares Ultra Russell 2000

0.01%

Global X Russell 2000 ETF

0.01%

iShares Russell 2000 ETF

0.01%

Fidelity Enhanced Small Cap ETF

iShares Micro-Cap ETF

佔比0.06%

SPDR S&P International Small Cap ETF

佔比0.04%

iShares Biotechnology ETF

佔比0.03%

iShares Russell 2000 Growth ETF

佔比0.02%

ProShares UltraPro Russell2000

佔比0.01%

ProShares Hedge Replication ETF

佔比0.01%

Proshares Ultra Russell 2000

佔比0.01%

Global X Russell 2000 ETF

佔比0.01%

iShares Russell 2000 ETF

佔比0.01%

Fidelity Enhanced Small Cap ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

ADC Therapeutics SA的前五大股東是誰？



ADC Therapeutics SA的前五大股東如下：
Redmile Group, LLC
持有股份：15.67M
佔總股份比例：13.93%。
HPWH TH AG
持有股份：8.67M
佔總股份比例：7.71%。
Point72 Asset Management, L.P.
持有股份：7.76M
佔總股份比例：6.90%。
Prosight Capital
持有股份：10.47M
佔總股份比例：9.30%。
OrbiMed Advisors, LLC
持有股份：5.91M
佔總股份比例：5.25%。